Hudlický's research passes a major milestone in licensing impact
Published on April 30 2012
Tomáš Hudlický, the Brock Professor of Chemistry who is also Canada Research Chair in Biocatalysis, has recently passed the $1-million mark in revenues generated through licensing agreements for processes developed in his labs.
Over the past six years, Hudlický has been working closely with the Georgia-based pharmaceutical company Noramco. During that time the Hudlický research group has come up with new processes for the manufacture of important medicinal agents for pain control and alcohol and drug addiction.
In addition to the licence agreements for scientific developments, this successful research relationship has provided Brock University with around $850,000 in research funding, said John Wilson, director of Business Development and Commercialization in the University's Office of Research Services.